PRA Completes 20th First in Human Biologics Trial

Article

Applied Clinical Trials

PRA announced it has completed its 20th first in human trial with biologics.

PRA announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience. Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.